Biogen signs collaborative agreement with Innocare to use orelabrutinib as potential therapy for multiple sclerosis

WORLD – Biogen and Innocare, a biopharmaceutical company rooted in China, have signed a license and a collaboration agreement for the use of Orelabrutinib that could potentially be used to treat multiple sclerosis. Under the terms of the agreement, Biogen will have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China, while Innocare will retain exclusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China. InnoCare will receive a US$125M upfront payment and is eligible to…

Read More